Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis

BMC Immunology

Iraklis Tsangaris³  Georgia Damoraki⁶  Georgia Dougekou⁶  Georgios Adamis¹  Maria Pavlaki⁵  Nikolaos Antonakos⁶  Maria Patrani²  Maria Raftogiannis⁶  Marina Koupetori⁴  Androniki Marioli⁷ 

[1] 1st Department of Internal Medicine, G.Gennimatas General Hospital, Athens, 11527, Greece;Intensive Care Unit, Korgialeneion-Benakeion Hospital, Athens, 11526, Greece;2nd Critical Care Department, “Attikon” University Hospital, 1 Rimini Str., Athens 12462, Greece;1st Department of Internal Medicine, Thriasio General Hospital, Elefsis, 19600, Greece;Department of Internal Medicine, Argos General Hospital, Argos, 21200, Greece;4th Department of Internal Medicine, Medical School, University of Athens, Athens, 12462, Greece;2nd Department of Internal Medicine, Sismanogleion General Hospital, Athens, 15126, Greece

关键词: sTREM-1, Monocytes;    TREM-1;    Outcome;    Sepsis;   

Others  :  1127904
DOI  :  10.1186/s12865-014-0063-y

 received in 2014-09-16, accepted in 2014-12-15,  发布年份 2014

【 摘 要 】

Background

TREM-1 (triggering receptor expressed on myeloid cells), a receptor expressed on neutrophils and monocytes, is upregulated in sepsis and seems to tune the inflammatory response. We explored the expression of TREM-1 at the gene level and on cell membranes of monocytes and association with clinical outcome.

Methods

Peripheral venous blood was sampled from 75 septic patients (39 patients with sepsis, 25 with severe sepsis and 11 with septic shock) on sepsis days 1, 3 and 7. TREM-1 on monocytes was measured by flow cytometry; gene expression of TREM-1 in circulating mononuclear cells was assessed by real-time PCR. sTREM-1 was measured in serum by an enzyme immunoassay.

Results

Although surface TREM-1, sTREM-1 and TREM-1 gene expression did not differ between sepsis, severe sepsis and septic shock on day 1, survivors had greater expression of surface TREM-1 on days 3 and 7 compared to non-survivors. sTREM-1 on non-survivors decreased on day 3 compared to baseline. Patients with increase of monocyte gene expression of TREM-1 from day 1 to day 3 had prolonged survival compared to patients with decrease of gene expression of TREM-1 from day 1 to day 3 (p: 0.031).

Conclusions

Early decrease of gene expression of TREM-1 in monocytes is associated with poor outcome. A reciprocal decrease of the pro-inflammatory surface receptor TREM-1 linked with sepsis-induced immunosuppression may be part of the explanation.

【 授权许可】

   
2014 Marioli et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Dombrovskiy VY, Martin AA, Sunderram J, Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-50.
• [2]Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 2014, 311:1308-16.
• [3]Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A: Association between source of infection and hospital mortality in patients who have septic shock. Am J Resp Crit Care Med 2014, 189:1204-13.
• [4]Arndt P, Abraham E: Immunological therapies for sepsis. Intensive Care Med 2001, 27(S1):S104-15.
• [5]Kotsaki A, Giamarellos-Bourboulis EJ: Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs 2012, 17:379-91.
• [6]Bouchon A, Dietrich J, Colonna M: Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000, 164:4991-5.
• [7]Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, Kollias S, Siasiakou S, Koronaios A, Zakynthinos S, Armaganidis A, Giamarellou H, Roussos C: Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock? Clin Exp Immunol 2005, 142:62-7.
• [8]Ford J, McVicar D: TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009, 21:38-46.
• [9]Dower K, Ellis DK, Saraf K, Jelinsky SA, Lin LL: Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide. J Immunol 2008, 180:3520-34.
• [10]Gibot S, Massin F, Marcou M, Taylor V, Stidwill R, Wilson P, Singer M, Bellingan G: TREM-1 promotes survival during septic shock in mice. Eur J Immunol 2007, 37:456-66.
• [11]Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, Yan P, Jia Y, Feng D, Xie L: Value of soluble TREM-1, procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia among sepsis patients with new fever in intensive care units: a prospective cohort study. BMC Infect Dis 2012, 12:157. BioMed Central Full Text
• [12]Gibot S, Cravoisy A, Kolopp-Sarda MN, Béné MC, Faure G, Bollaert PE: Time-course of sTREM (soluble triggering receptor expressed on myeloid cells)-1, procalcitonin, and C-reactive protein plasma concentrations during sepsis. Crit Care Med 2005, 33:792-6.
• [13]Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, Karagianni V, Antonopoulou A, Veloni V, Giamarellou H: Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care 2006, 10:R166. BioMed Central Full Text
• [14]Adib-Conquy M, Cavaillon JM: Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009, 101:36-47.
• [15]Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, Kardara M, Orfanos SE, Kotanidou A, Giamarellos-Bourboulis EJ: Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: correlation with monocyte gene expression. J Crit Care 2012, 27:294-300.
• [16]Poukoulidou T, Spyridaki A, Michailidou I, Kopterides P, Pistiki A, Alexiou Z, Chrisofos M, Dimopoulou I, Drimoussis P, Giamarellos-Bourboulis EJ, Koutelidakis I, Marioli A, Mega A, Orfanos SE, Theodorakopoulou M, Tsironis C, Maggina N, Polychronopoulos V, Tsangaris I: TREM-1 expression on neutrophils and monocytes of septic patients: relation to the underlying infection and the implicated pathogen. BMC Infect Dis 2011, 11:309. BioMed Central Full Text
• [17]Levy M, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 2003, 31:1250-6.
• [18]Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. A randomized trial. Am J Respir Crit Care Med 2006, 174:84-93.
• [19]Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med 1997, 15:148-51.
• [20]Calandra T, Cohen J: The international Sepsis Forum Consensus definitions of infections in the intensive care unit. Crit Care Med 2005, 33:1639-48.
• [21]Kollef MH: Appropriate antibiotic therapy for ventilator-associated pneumonia and sepsis: a necessity, not an issue for debate. Intensive Care Med 2003, 29:147-9.
• [22]Wang F, Liu S, Wu S, Zhu Q, Ou G, Liu C, Wang Y, Liao Y, Sun Z: Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis. Cell Immunol 2012, 272:251-8.
• [23]Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H: Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine 2013, 61:112-7.
• [24]Tao F, Peng L, Li J, Yao H: Association of serum myeloid cells of soluble triggering receptor-1 level with myocardial dysfunction in patients with severe sepsis. Mediators Inflamm 2013, 2013:819246.
• [25]Oda S, Sadahiro T, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H: Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine 2013, 61:112-7.
• [26]Kwan A, Hubank M, Rashid A, Klein N, Peters MJ: Transcriptional instability during evolving sepsis may limit biomarker based risk stratification. PLoS One 2013, 8:e60501.
• [27]Turrel-Davin F, Venet F, Monnin C, Barbalat V, Cerrato E, Pachot A, Lepape A, Alberti-Segui C, Monneret G: mRNA-based approach to monitor recombinant gamma-interferon restoration of LPS-induced endotoxin tolerance. Crit Care 2011, 15:R252. BioMed Central Full Text
• [28]Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-50.
• [29]Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD II, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-605.
• [30]Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, Netea M, Pickkers P: Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med 2012, 186:838-45.